相关实验视频

Updated: Jan 13, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

向谷氨胺载体作为一种新型药物疗法,用于突肉瘤

Tran Duc Thanh^1,2,3, Naoki Takada¹, Hana Yao¹

¹Department of Orthopedic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.

|January 10, 2026

概括

突肉瘤 (SS) 是一种依赖谷氨酸的癌症. 在临床前模型中,用V9302抑制ASCT2载体有效降低瘤生长,并诱导癌细胞死亡.

科学领域:

在瘤学瘤学.
癌症新陈代谢癌症新陈代谢
分子生物学分子生物学

背景情况:

突肉瘤 (SS) 是一种软组织癌症,在晚期病例中结果不佳.
针对癌症新陈代谢,特别是谷氨酸新陈代谢,提供了一个潜在的治疗途径.
ASCT2是一种谷氨胺转运体,可能是SS中可行的治疗标.

研究的目的:

为了研究突肉瘤中的谷氨胺依赖性.
为了评估ASCT2抑制的治疗潜力,在SS中使用V9302进行SS.
评估ASCT2表达在SS和脂肪肉瘤 (LPS) 组织中的表达.

主要方法:

免疫组织化学 (IHC) 来评估ASCT2表达.
使用SS细胞系和患者衍生的细胞进行体外研究,以评估谷氨酸缺乏和V9302的影响.
西方涂抹和流动细胞测量来分析信号通路和亡.
在体内异种移植模型以确定V9302的疗效和毒性.

主要成果:

与正常组织和LPS相比,SS组织中的ASCT2表达显著更高.
在SS细胞的繁殖过程中,它们对谷氨胺有很强的依赖.
通过抑制AKT/mTOR通路并诱导亡,V9302治疗降低了SS细胞活力.
在体内,V9302有效抑制了瘤生长,没有观察到系统性毒性.

结论:

突肉瘤是一种依赖谷氨酸的癌症,强调ASCT2作为一个有前途的治疗标.
在临床前的SS模型中,ASCT2抑制剂V9302显示出显著的治疗疗效.
V9302值得进一步研究,因为它可能是对突肉瘤的潜在治疗方法.

关键词:

在 AKT/mTOR 路径上.在 ASCT2 中,ASCT2 是指 ASCT2 的类型.V9302 这是一个很好的例子.谷氨胺的代谢过程突性肉瘤 (Synovial Sarcoma) 是一个突性肉瘤.

更多相关视频

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

Glutamine Flux Imaging Using Genetically Encoded Sensors

Glutamine Flux Imaging Using Genetically Encoded Sensors

Published on: July 31, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...